Literature DB >> 8311112

4A11, a monoclonal antibody recognizing a novel antigen expressed on aberrant vascular endothelium. Upregulation in an in vivo model of contact dermatitis.

A E Koch1, B J Nickoloff, J Holgersson, B Seed, G K Haines, J C Burrows, S J Leibovich.   

Abstract

We describe the production and characterization of a novel monoclonal antibody (MAb) that recognizes a human endothelial cell antigen expressed mainly in inflamed and malignant disease states. We have used immunohistochemistry to determine the spectrum of reactivity of this MAb compared with that of a MAb to factor VIII-related antigen (MAb FVIII). MAb 4A11 does not react with several myeloid or lymphoid cell lines or with peripheral blood cells. Unlike MAb FVIII, MAb 4A11 does not react with platelets. MAb 4A11 reacts with most vascular endothelial cells in lymphoid tissue but with few (< 10%) endothelial cells in thymus, spleen, liver, lung, adrenal gland, placenta, testes, and skin. MAb 4A11 detects endothelial cells in diseased tissues such as rheumatoid and osteoarthritic synovium and psoriatic skin. Vascular endothelial cells in both adrenal tumors and cutaneous Kaposi's sarcomas lesions are MAb 4A11 reactive. In vitro the 4A11 antigen is not detectable on cultured human umbilical vein endothelial cells and its expression is not induced on these cells by treatment with lipopolysaccharide, interferon-gamma, interleukin-1 and -6, or tumor necrosis factor-alpha. However, in an in vivo model of allergic contact dermatitis the 4A11 antigen is upregulated differentially from other endothelial markers such as E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1. In this dermal model of inflammation, poison ivy extract is applied to the skin and biopsies taken at 0, 6, and 24 hours. In addition to focal keratinocyte expression, 4A11 antigen is found on 11% of dermal endothelial cells at time 0 and antigen expression increases with time until 24 hours, when 4A11 antigen is present on 63% of the endothelial cells. Using thin layer chromatography, MAb 4A11 reacts with the H-5-2 [Fuc alpha 2Gal beta 4GlcNAc beta 3Gal beta 4Glc beta 1Cer] and Lewis(y)-6 [Fuc alpha 2Gal beta 4(Fuc alpha 3)GlcNAc beta 3Gal beta 4-Glc beta 1Cer] blood group glycolipids. The presence of the novel 4A11 antigen in inflamed and malignant tissues containing many blood vessels and its differential upregulation in allergic contact dermatitis may signify an important function for this antigen in the inflammatory process.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8311112      PMCID: PMC1887152     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  66 in total

1.  Release of interleukin-1 from human synovial tissue in vitro.

Authors:  D D Wood; E J Ihrie; D Hamerman
Journal:  Arthritis Rheum       Date:  1985-08

2.  Isolation of an interleukin-1-like factor from human joint effusions.

Authors:  D D Wood; E J Ihrie; C A Dinarello; P L Cohen
Journal:  Arthritis Rheum       Date:  1983-08

3.  Involvement of sialic acid on endothelial cells in organ-specific lymphocyte recirculation.

Authors:  S D Rosen; M S Singer; T A Yednock; L M Stoolman
Journal:  Science       Date:  1985-05-24       Impact factor: 47.728

4.  Lymphocyte recognition of lymph node high endothelium. VII. Cell surface proteins involved in adhesion defined by monoclonal anti-HEBFLN (A.11) antibody.

Authors:  R A Rasmussen; Y H Chin; J J Woodruff; T G Easton
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

5.  Expression of Ia-like antigens by human vascular endothelial cells is inducible in vitro: demonstration by monoclonal antibody binding and immunoprecipitation.

Authors:  J S Pober; M A Gimbrone
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

6.  A cell-surface molecule involved in organ-specific homing of lymphocytes.

Authors:  W M Gallatin; I L Weissman; E C Butcher
Journal:  Nature       Date:  1983 Jul 7-13       Impact factor: 49.962

7.  Blood group type glycosphingolipids of human kidneys. Structural characterization of extended globo-series compounds.

Authors:  J Holgersson; P A Jovall; B E Samuelsson; M E Breimer
Journal:  Glycoconj J       Date:  1991-10       Impact factor: 2.916

8.  A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans.

Authors:  M Salmi; S Jalkanen
Journal:  Science       Date:  1992-09-04       Impact factor: 47.728

9.  Tissue specificity of glycosphingolipids as expressed in pancreas and small intestine of blood group A and B human individuals.

Authors:  M E Breimer
Journal:  Arch Biochem Biophys       Date:  1984-01       Impact factor: 4.013

10.  Interleukin-1 activation of vascular endothelium. Effects on procoagulant activity and leukocyte adhesion.

Authors:  M P Bevilacqua; J S Pober; M E Wheeler; R S Cotran; M A Gimbrone
Journal:  Am J Pathol       Date:  1985-12       Impact factor: 4.307

View more
  14 in total

Review 1.  The role of angiogenesis in rheumatoid arthritis: recent developments.

Authors:  A E Koch
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

2.  TLR5, a novel and unidentified inflammatory mediator in rheumatoid arthritis that correlates with disease activity score and joint TNF-α levels.

Authors:  Nathan D Chamberlain; Olga M Vila; Michael V Volin; Suncica Volkov; Richard M Pope; William Swedler; Arthur M Mandelin; Shiva Shahrara
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

3.  IL-17 contributes to angiogenesis in rheumatoid arthritis.

Authors:  Sarah R Pickens; Michael V Volin; Arthur M Mandelin; Jay K Kolls; Richard M Pope; Shiva Shahrara
Journal:  J Immunol       Date:  2010-02-19       Impact factor: 5.422

4.  Relationship between neovascularization and degenerative changes in herniated lumbar intervertebral discs.

Authors:  Tõnu Rätsep; Ave Minajeva; Toomas Asser
Journal:  Eur Spine J       Date:  2013-06-05       Impact factor: 3.134

Review 5.  Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy.

Authors:  S B Fox; A L Harris
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

6.  Role of the CCL21 and CCR7 pathways in rheumatoid arthritis angiogenesis.

Authors:  Sarah R Pickens; Nathan D Chamberlain; Michael V Volin; Richard M Pope; Nicholas E Talarico; Arthur M Mandelin; Shiva Shahrara
Journal:  Arthritis Rheum       Date:  2012-08

7.  Characterization of interleukin-7 and interleukin-7 receptor in the pathogenesis of rheumatoid arthritis.

Authors:  Sarah R Pickens; Nathan D Chamberlain; Michael V Volin; Richard M Pope; Nicholas E Talarico; Arthur M Mandelin; Shiva Shahrara
Journal:  Arthritis Rheum       Date:  2011-10

8.  Characterization of CCL19 and CCL21 in rheumatoid arthritis.

Authors:  Sarah R Pickens; Nathan D Chamberlain; Michael V Volin; Richard M Pope; Arthur M Mandelin; Shiva Shahrara
Journal:  Arthritis Rheum       Date:  2011-04

9.  Aberrant expression of histo-blood group A type 3 antigens in vascular endothelial cells in inflammatory sites.

Authors:  Mizuho Nosaka; Yuko Ishida; Aki Tanaka; Takahito Hayashi; Tomoko Miyashita; Chikako Kaminaka; Wolfgang Eisenmenger; Fukumi Furukawa; Akihiko Kimura
Journal:  J Histochem Cytochem       Date:  2007-11-12       Impact factor: 2.479

10.  Ovarian angiogenesis. Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression.

Authors:  H G Augustin; K Braun; I Telemenakis; U Modlich; W Kuhn
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.